

CORRECTION

Open Access



Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Aleksandar Sekulic^{1*}, Michael R. Migden², Nicole Basset-Seguín³, Claus Garbe⁴, Anja Gesierich⁵, Christopher D. Lao⁶, Chris Miller⁷, Laurent Mortier⁸, Dedee F. Murrell⁹, Omid Hamid¹⁰, Jorge F. Quevedo¹¹, Jeannie Hou¹², Edward McKenna¹², Natalie Dimier¹³, Sarah Williams¹³, Dirk Schadendorf¹⁴, Axel Hauschild¹⁵ and for the ERIVANCE BCC Investigators

Correction to: BMC Cancer

DOI 10.1186/s12885-017-3286-5

Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:

Fig. 1 Swimlane plot of time to response, treatment duration, and duration of follow-up for efficacy-evaluable patients who achieved response in the mBCC cohort (a), those in the laBCC cohort with treatment duration > 20 months (b), and those in the laBCC cohort who were treated for < 20 months (c). laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma.

Author details

¹Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. ²Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA. ³Service de Dermatologie, Hôpital Saint-Louis, 1 av Claude Vellefaux, 75010 Paris, France. ⁴Studienzentrum Dermatologische Onkologie, Universitätsklinikum Tübingen, Liebermeisterstr. 25, 72074 Tübingen, Germany. ⁵Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany. ⁶University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA. ⁷Department of Dermatology, University of Pennsylvania Medical Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. ⁸Clinique de Dermatologie, Hôpital Claude Huriez, Inserm U1189, Lille, France. ⁹Dermatology Department, St George Clinical School, University of New South Wales, Grey Street, Sydney 2217, Australia. ¹⁰The Angeles Clinic and Research Institute, 1818 Wilshire Boulevard, California, Los Angeles, USA. ¹¹Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. ¹²Genentech,

Inc., 1 DNA Way, South San Francisco, California 94080, USA. ¹³Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW, UK. ¹⁴Klinikum für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. ¹⁵Universitätsklinikum Schleswig-Holstein, Schittenhelmstr. 7, D-24 105 Kiel, Germany.

Received: 2 April 2019 Accepted: 2 April 2019

Published online: 18 April 2019

Reference

1. Sekulic A, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. *BMC Cancer*. 2017;17:332. <https://doi.org/10.1186/s12885-017-3286-5>.

* Correspondence: sekulic.aleksandar@mayo.edu

¹Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA

Full list of author information is available at the end of the article

